Phylogica Ltd (PYC), a leading Australian peptide drug discovery company, announced that it has been granted a new patent by the Australian Patent Office. This worldwide patent is pending in multiple other jurisdictions, including the USA, Europe and Japan. The patent covers methods of producing designed, synthetic libraries of peptides that are predicted to be rich in structure and, therefore, more likely to be drug-like than conventional random peptides.
Dr Paul Watt, Phylogica’s Chief Executive Officer, commented on the news: “The allowance of this patent adds another powerful component to Phylogica’s Phylomer platform and opens up new opportunities in the emerging field of synthetic biology. This patent further strengthens our core IP portfolio, which already includes multiple granted worldwide patents. It maintains Phylogica’s dominant intellectual property position over the construction and screening of the world’s most structurally diverse source of peptides.”
Phylogica Limited (PYC) is a biotechnology company based in Perth, Australia, and the UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics.
